Skip to main content

Table 1 Baseline demographics

From: Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin

  

Median (IQR)/n(%)

Age (years)

 

66(61–71)

Initial PSA (ng/mL)

 

8.2(5.3–15.5)

Pathologic T stage

2

741(46.3)

 

3

825(51.6)

 

4

33(2.1)

Lymph node metastasis

(−)

1555(97.2)

 

(+)

45(2.8)

Pathologic Gleason score

≤6

434(27.1)

 

7

780(48.8)

 

≥8

386(24.1)

LVI

(−)

1482(92.6)

 

(+)

118(7.4)

Margin status

(−)

840(52.5)

 

(+)

760(47.5)

BCR

No

934(58.4)

 

Yes

666(41.6)

Distant metastasis

Present

1505(94.1)

 

Absent

95(5.9)

Cancer-specific mortality

Survived

1552(97.0)

 

Expired

48(3.0)

Follow-up duration (months)

 

33.1(18.4–53.8)

  1. LVI lymphovascular invasion; PSA prostate-specific antigen; NHT neoadjuvant hormone therapy; BCR biochemical recurrence